Apr 03, 2018 12:01 pm UTC| Business
Denver, Colo., April 03, 2018 -- Research has shown that children of color are more likely to succeed when they have a teacher of the same race. Yet Native children are much more likely to have a white teacher than a...
Next Graphite Announces Further Updates To Aukam Plant Construction & Mining Progress
Apr 03, 2018 12:01 pm UTC| Business
LOS ANGELES, CA, April 03, 2018 -- Next Graphite, Inc. (OTC PINK: GPNE) ("Next Graphite," "GPNE" or the "Company"), a graphite development company out of the Republic of Namibia and co-license joint interest holder in...
Imagin Medical Announces Private Placement
Apr 03, 2018 12:01 pm UTC| Business
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s...
PriceSpider Innovation Team Continues to Fortify Company Success
Apr 03, 2018 12:01 pm UTC| Business
IRVINE, Calif., April 03, 2018 -- PriceSpider, an advanced retail data and analytics company that provides insights about consumer purchasing behavior – is proud to spotlight its professional lineup of retail technology...
Hershey Announces Cocoa For Good, the Company’s Half-Billion Dollar Sustainable Cocoa Strategy
Apr 03, 2018 12:01 pm UTC| Business
HERSHEY, Pa., April 03, 2018 -- The Hershey Company (NYSE:HSY) today announced Cocoa For Good, its holistic cocoa sustainability strategy. The comprehensive strategy addresses the most pressing issues facing...
HTG Announces New Patent for Its Technology Issued in Japan
Apr 03, 2018 12:01 pm UTC| Business
Patent covers nuclease protection methods for detection of nucleotide variants TUCSON, Ariz., April 03, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for...
Apr 03, 2018 12:01 pm UTC| Business
SAN DIEGO, April 03, 2018 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective...